On July 1, 2022 RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, reported the progress of its leading candidate RS-0139’s Phase I trial (RS-001) on NSCLC (Press release, RS Research, JUL 1, 2022, View Source [SID1234616793]). Designing drug candidates with improved safety profile and superior therapeutic index based on its proprietary SagittaTM drug delivery technology, RS Research will advance to the next dose cohort following the positive review of the safety data from the dosing of the first cohort by the Independent Data Monitoring Committee (IDMC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Esteemed medical experts of IDMC recommended that the clinical trial continues as planned and escalates from the first dose of 75 mg/m2 to the next dose of 100 mg/m2. RS-0139 was designed for the treatment of various cancer indications, with the initial phase I ongoing with NSCLC patients. SagittaTM technology enables nanomedicine to target the receptors on the tumor cell surface, reducing side effects sparing the healthy cells from its harmful effects.
Five drug candidates in RS Research pipeline address the unmet needs of over 6 million newly diagnosed oncology patients. According to World Health Organization, in 2020 lung cancer patients alone constituted 2.2 million of this population. RS Research was founded in 2015 by Prof. Rana Sanyal and Sena Nomak as an academic spin-off from Boğaziçi University to take the necessary R&D and commercialization steps for bringing innovative therapies to patients. The company raised funds from national and international funding agencies along with over 14 million USD from investors including GEN Pharmaceuticals, Eczacıbaşı Momentum, Istanbul Asset Management and ACT Venture Partners.